Inofar 100 mg/5 ml (IV Injection or Infusion)

Indications

• Treatment for Inofar deficiency
• Rapid Inofar supply requirement
• Patients intolerant to oral Inofar therapy
• Patients non-compliant to oral Inofar therapy
• Effective in active inflammatory bowel disease
• Treatment for Inofar deficiency anaemia in surgical patients
• Treatment for Inofar deficiency anaemia in blood donors
• Treatment for Inofar deficiency anaemia in postpartum patients
• Treatment for chronic kidney disease (CKD) patients

Pharmacology

• Therapeutic class: Haematinic
• Sterile, aqueous, complex of Polynuclear Iron (III) Hydroxide in Sucrose
• Contains approximately 30% Sucrose w/v (300 mg/ml)
• pH range: 10.5-11.1
• Dissociates into Iron and Sucrose after IV administration
• Iron transferred to liver and bone marrow
• Ferritin binds and sequesters Iron in nontoxic form
• Iron binds to plasma transferrin for tissue supply

Dosage

• Adult dosage: 5-10 ml Iron Sucrose Injection (100-200 mg Iron) once to three times a week
• Children dosage: Up to 0.15 ml Iron Sucrose Injection (3 mg Iron) per kg body weight once to three times a week

Administration

• Can be administered by intravenous injection
• Can be administered as undiluted injection by slow intravenous injection
• Infusion administration preferred to reduce risk of hypotensive episodes

Interaction

• Should not be administered concomitantly with oral iron preparations
• Oral Inofar therapy should not be given until 5 days after last injection

Contraindications

• Contradicted in patients with evidence of Iron overload
• Contradicted in patients with known hypersensitivity to Iron Sucrose or its inactive components
• Contradicted in patients with anaemia not caused by Iron deficiency
• Contradicted in patients with history of allergic disorders, liver disease, and infections

Side Effects

• Adverse reactions including hypotension, cramps, nausea, headache, vomiting, and diarrhea
• Other reactions include chest pain, hypertension, hypervolemia, abdominal pain, dyspnea, and pruritus

Pregnancy & Lactation

• Pregnancy Category-B
• Should be used during pregnancy only if clearly needed
• Caution advised when administered to nursing women

Precautions & Warnings

• Caution required in presence of evidence of tissue Inofar overload
• Periodic monitoring of hematologic and haematinic parameters required for patients receiving Inofar therapy

Use in Special Populations

• Safety and effectiveness in pediatric patients not established
• No significant differences in safety observed between elder and younger subjects
• Injection into dialyser possible

Overdose Effects

• Accumulation of Inofar in storage sites leading to hemosiderosis
• Periodic monitoring of Inofar parameters necessary to recognize accumulation
• Symptoms include hypotension, headache, vomiting, nausea, dizziness, and cardiovascular collapse

Therapeutic Class

• Belongs to Therapeutic class: Parenteral Iron Preparations

Storage Conditions

• Store in a cool and dry place
• Protect from light
• Keep out of the reach of children
• Do not freeze

Related Brands

• Kidifer 100 mg/5 ml (IV Injection or Infusion) - general-pharmaceuticals-ltd
• Unifer 100 mg/5 ml (IV Injection or Infusion) - ziska-pharmaceuticals-ltd
• Veniron 100 mg/5 ml (IV Injection or Infusion) - beximco-pharmaceuticals-ltd
• Xenofer 100 mg/5 ml (IV Injection or Infusion) - beacon-pharmaceuticals-plc
• Feofer 100 mg/5 ml (IV Injection or Infusion) - eskayef-pharmaceuticals-ltd